Market Intelligence, Clinical Progress, and High-Purity Reagents for Prostate Cancer Theranostic Development.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for PSMA drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | PSMA (FOLH1) ECD-Fc Fusion Protein High purity (>95%), Endotoxin <1EU/ug. Sequence Verified. HEK293 Expressed (Native Glycosylation). |
View PSMA Products |
| Gene Delivery | PSMA (FOLH1) Promise-ORF Lentivirus Full-length ORF for stable cell line construction. High titer, Puromycin selection. |
View PSMA Products |
| Benchmark Ab | Anti-PSMA (Sequence of J591, Clinical Stage mAb) Recombinant chimeric antibody. Positive control for RLT/ADC development. |
View PSMA Products |
| Validator | PSMA siRNA Set (3 Unique Targets) For knockdown verification and specificity control. Sequence Verified. |
View PSMA Products |
| Related Target A | STEAP1 Synergistic prostate-specific membrane antigen for dual-targeting (bispecific / ADC) strategies. |
View STEAP1 Products |
| Related Target B | FOLR1 Folate receptor for selectivity screening and off-target counter-assays. |
View FOLR1 Products |
| Related Target C | AR (Androgen Receptor) Key resistance mechanism driver; mutant protein panels for combination therapy studies. |
View AR Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Cross-species toxicology (Cyno/Mouse) | Human/Cyno/Mouse PSMA ortholog proteins with >95% purity; Sequence verified by Mass Spec. |
| Internalization efficiency (ADC/RLT) | High-purity ECD-Fc preserves native conformation; low endotoxin (<1EU/ug) for pH-dependent uptake assays. |
| Subfamily off-target liability (GCPIII/NAALAD2) | Homolog panel (NAALAD2) strictly verified for counter-screening. |
| Lack of clinical controls | Clinical benchmark antibodies (J591, PSMA-617 mimetics) included as positive controls. |
| False positives in binding assays | Validated siRNA included for target-specificity verification. |
Live PSMA R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for PSMA therapeutics is intensifying, with Novartis's Pluvicto (177Lu-PSMA-617) establishing the Radioligand Therapy (RLT) standard in metastatic Castration-Resistant Prostate Cancer (mCRPC). As first-generation therapies reach the clinic, the next wave of R&D is targeting toxicity mitigation (salivary gland/kidney uptake) and acquired resistance mechanisms. Major players are shifting from simple binding affinity to engineering pH-sensitive release, masked pro-drugs activated by tumor microenvironment, and combination regimens with AR pathway inhibitors.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Radioligand Therapy (RLT) | Novartis, POINT/Lilly, Telix | mCRPC | Binding affinity & internalization rate (Need high-purity ECD-Fc for SPR / Cell uptake) |
| ADC | AbbVie, Ambrx, Daiichi Sankyo/AstraZeneca | mCRPC, localised PC | Endocytosis efficiency & lysosomal trafficking (Need stable cell lines via Lentivirus) |
| Bispecific TCE | Amgen, Harpoon Therapeutics, Janssen | mCRPC | Heterodimer validation & tumour vs. tissue selectivity (Need cross-reactive Abs & ortholog panel) |
| Diagnostic Imaging | Telix, Lantheus | Staging | Specificity vs. GCPIII (Need NAALAD2 protein for counter-screening) |
| Small Molecule Inhibitor | Academic / Pharma Consortia | Neuroprotection (GCPII), Oncology | Selectivity assay (Need mutant vs WT proteins; GCPIII/NAALAD2 counter-screen) |
Molecular Differentiation & Assay Strategy
To develop best-in-class PSMA therapies, several molecular differentiation dimensions are critical:
- Affinity engineering: Ultra-high affinity may exacerbate renal toxicity. Moderate affinity with pH-sensitive binding improves tumour penetration and reduces off-target uptake. SPR/BLI screening with high-purity ECD-Fc is essential.
- Internalization efficiency: For ADC and RLT, rapid internalization is key. pHrodo-based assays with stable PSMA-overexpressing cell lines enable quantitative measurement.
- Toxicity mitigation: PSMA expression in salivary glands and kidneys causes dose-limiting toxicities. Masked (conditionally activated) prodrugs and pH-dependent release mechanisms are emerging. Assays need to capture pH-dependent binding kinetics.
- Counter-screen against GCPIII/NAALAD2: Avoid off-target neurotoxicity by ensuring >100-fold selectivity over NAALAD2 using recombinant protein panels.
- Cross-species validation: For non-human primate toxicology studies, confirm binding and internalization on cynomolgus PSMA ortholog.
TarMart provides the full reagent toolkit (ECD-Fc, lentivirus, siRNA, benchmark antibodies) to support each of these assay needs.
Conclusion
PSMA remains the premier target for prostate cancer theranostics. As the competitive landscape evolves, success will depend on molecular differentiation in affinity, internalization, selectivity, and safety. TarMart's high-quality reagents and cell-line tools accelerate the development of next-generation RLTs, ADCs, and bispecifics.